The Bristol-Celgene merger is approved. Here are 8 challenges ahead
Like Dustin Hoffman and Katharine Ross in the last scene of “The Graduate,” Bristol-Myers Squibb and Celgene got what they wanted. Now they’ll have to get used to one another’s…
After months of horse-trading, hand-wringing, and heated debate, the $74 billion merger of Bristol-Myers Squibb and Celgene was finally approved by shareholders on Friday. “We’re very excited about the new company,” Giovanni Caforio, Bristol’s chairman and CEO, said at the meeting.
Now what?
Like Dustin Hoffman and Katharine Ross in the last scene of “The Graduate,” the two biopharma newlyweds got what they wanted, and now they’ll have to get used to one another’s idiosyncrasies. That means navigating a patent cliff, dealing with rough market dynamics, and trying to keep key employees from updating their résumés.
Here’s a look at the biggest issues facing Bristol-Myers and
